Keyphrases
RNA-dependent RNA Polymerase (RdRP)
100%
Foot-and-mouth Disease Virus
100%
3Dpol
83%
Binding Pocket
33%
Non-competitive Inhibitor
33%
Immune Response
16%
Viral
16%
EC50
16%
Site-directed mutagenesis
16%
Nucleic Acids
16%
Luciferase
16%
Viral Replication
16%
Polymerase
16%
Design Study
16%
Inhibitor Binding
16%
Inhibition Mechanism
16%
Virus Production
16%
Virus-infected Cell
16%
Structure-based Drug Design
16%
Virus Subtypes
16%
Novel Inhibitors
16%
Catalytic Site
16%
Picornavirus
16%
Molecular Modeling Studies
16%
Molecular Docking Studies
16%
Livestock Production
16%
Enzyme Kinetic Study
16%
Foot-and-mouth Disease Virus Infection
16%
FMD Outbreaks
16%
Emergency Vaccination
16%
Medicine and Dentistry
RNA Directed RNA Polymerase
100%
Foot and Mouth Disease Virus
100%
Competitive Inhibition
28%
Immune Response
14%
Virus Infection
14%
Luciferase
14%
Virus Replication
14%
Site-Directed Mutagenesis
14%
Polymerase
14%
Enzyme Kinetics
14%
Nucleic Acid
14%
Molecular Model
14%
Picornaviridae
14%
Docking (Molecular)
14%
Antiviral Drug
14%
Virus
14%
Biochemistry, Genetics and Molecular Biology
RNA-dependent RNA Polymerase
100%
Foot and Mouth Disease Virus
100%
Competitive Inhibition
28%
Luciferase
14%
Immune Response
14%
Site-Directed Mutagenesis
14%
Nucleic Acid
14%
Molecular Model
14%
EC50
14%
Polymerase
14%
Virus Replication
14%
Enzyme Kinetics
14%
Docking (Molecular)
14%
Picornaviridae
14%
EC90
14%
Immunology and Microbiology
RNA-dependent RNA Polymerase
100%
Foot and Mouth Disease Virus
100%
Competitive Inhibition
28%
Immune Response
14%
Viral Disease
14%
EC50
14%
Viral Replication
14%
Site Directed Mutagenesis
14%
Molecular Model
14%
Picornaviridae
14%
Molecular Docking
14%
Enzyme Kinetics
14%
Virus
14%
EC90
14%
Pharmacology, Toxicology and Pharmaceutical Science
RNA Directed RNA Polymerase
100%
Foot and Mouth Disease Virus
100%
Competitive Inhibitor
28%
Virus Infection
14%
Luciferase
14%
Nucleic Acid
14%
Site-Directed Mutagenesis
14%
Enzyme Kinetics
14%
Picornaviridae
14%
Antiviral Drug
14%
EC50
14%
Structure-Based Drug Design
14%